Wearable tech may outsmart the blood pressure cuff in preventing heart attacks

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 24 hour mean SBP ≥ 130 mmHg by cuffless ambulatory BP monitor * aged ≥30 and \<80 years * voluntarily decide to participate in this clinical trial and provide written informed consent after being adequately informed. * willing and able to comply with the requirements of the study protocol Exclusion Criteria: * Did not agree with this clinical trial and did not provide informed consent * Office SBP ≥ 190 mmHg, or diastolic BP (DBP) \< 60 mmHg. * Diagnosed secondary hypertension. * Hospitalization for stroke, myocardial infarction (MI) or unstable angina within the last 6 months * Coronary revascularization (percutaneous coronary intervention \[PCI\] or coronary artery bypass grafting \[CABG\]) within the last 12 months. * Planned to perform coronary revascularization (PCI or CABG) in the next 12 months. * History of sustained atrial fibrillation (AF) or ventricular arrhythmias at entry influencing the BP measurement of ring-type cuffless BP monitoring device. * Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial. * Underlying heart disease: Hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), rheumatic heart disease or congenital heart disease * Uncontrolled diabetes mellitus (serum fasting glucose \> 200 mg/dL or glycated hemoglobin \[HbA1c\] \>8%). * Severe liver dysfunction (alanine aminotransferase \[ALT\] \> 3 times the upper limit of normal (ULN) value). * Severe renal dysfunction (end stage renal disease \[ESRD\] on dialysis or estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73m², or serum creatinine \>2.5 mg/dL. * Malignancy history within 5 years. * Severe cognitive impairment or mental disorders. * Participating in other clinical trials other than observation registry